Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-30

Study Completion Date

2020-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Given the high prevalence of COVID19 illness (both SARS-CoV-2 RT-PCR confirmed and highly suspect cases) among healthcare workers (HCW) within the Montefiore Health System (MHS), hydroxychloroquine (HCQ) will be prescribed to healthcare workers who are at the highest risk for severe COVID19 illness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

NCT04435808

COVID-19

TERMINATED PHASE1/PHASE2

HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers

NCT04336748

Sars-CoV2 Infection Viral Healthcare Worker +1 more

WITHDRAWN PHASE3

Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?

NCT04374942

Pre-Exposure Prophylaxis Coronavirus SARS-CoV 2

TERMINATED PHASE3

Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease

NCT04429867

COVID-19

UNKNOWN PHASE4

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

NCT04333225

COVID-19

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID Coronavirus COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

Eligible participants will be offered the standard Montefiore HCQ dosing regimen of 400mg every 12 hours x 24 hours, then 400mg daily for remaining 4 days and complete a survey study

Group Type EXPERIMENTAL

Hydroxychloroquine

Intervention Type DRUG

400 mg tablet

Control Group

Participants who opt not to receive the study drug will also be invited to participate in the survey study assessing COVID19 symptoms

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydroxychloroquine

400 mg tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptomatic with COVID illness (either RT-PCR test confirmed or highly suspect clinical symptoms)
* Call into office within the first 7 days of illness
* Have any of the following high risk conditions:

* Age \>60
* HTN, CAD, or chronic heart disease
* Diabetes
* Chronic kidney disease
* Chronic lung disease
* Active or recent chemotherapy for malignancy
* Organ transplant
* Taking Immune-suppressing medications
* HIV with CD4 \<200 cells/mm3
* Experiencing at least one of the following high risk symptoms:

* Severe cough
* Fever 100.0F or greater
* Diarrhea
* Shortness of Breath
* Hypoxia